Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergan, Inc.
Licensing agreement signed to develop, market Lumigan in Japan
June 26th, 2004
Allergan, Inc., (AGN) and Senju Pharmaceutical announced that they have entered into an exclusive licensing agreement in Japan to market and develop Lumigan (Bimatoprost Ophthalmic solution - 0.03%) within the ophthalmic specialty area. Lumigan, a clinically proven, effective eye drop medication for lowering intraocular pressure (IOP), was first launched in the United States in 2001 and is currently marketed in more than 40 countries around the world. In 2003, global sales of Lumigan were $181 million and are currently projected to be between $210 and $235 million in 2004. Under the terms of the licensing agreement, Senju will be responsible for the...
Source: Law & Health Weekly (2004-06-26)
|
